As one of the fastest growing classes of medications, GLP-1 weight-loss drugs were originally brought on the market to treat diabetes
UV and visible light accelerate peptide degradation through photooxidation
Typical weekly dosing schedule (example shown follow your prescriber): Weeks 14: 0.25 mL (2.5 mg) once weekly (subcutaneous) Weeks 58: 0.5 mL (5 mg) once weekly Weeks 912: 0.75 mL (7.5 mg) once weekly Week 13 and onward: 1 mL (10 mg) once weekly One carton (4 kits) provides 4 weekly doses
Its a tri-agonist targeting three separate receptor systems simultaneously: The GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors
incorrect dosing may exacerbate these effects Gallbladder problems GLP-1 receptor agonist use has been associated with gallbladder disease, including gallstones and cholecystitis Hypoglycaemia If retatrutide is used alongside insulin or sulfonylureas, there is an increased risk of low blood glucose Call 999 or go to A&E immediately if you experience: Difficulty breathing, throat swelling, or any signs of anaphylaxis Severe abdominal pain (which may indicate pancreatitis or a gallbladder problem) Rapid heart rate, dizziness, or collapse following injection Contact your GP or NHS 111 if you experience: Persistent nausea, vomiting, or inability to tolerate food or fluids Signs of infection at the injection site (increasing redness, warmth, swelling, or discharge) Upper right abdominal pain or pain radiating to the shoulder (possible gallbladder symptoms) Any unexpected or concerning symptoms following use If you feel unwell after using an unlicensed injectable, stop use immediately and bring the vial and any packaging with you when seeking medical attention, as this will assist healthcare professionals in assessing your situation
Only your own care team can answer that for you
.png)
